SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
DARE reported Third Quarter 2026 results. The price and volatility reaction is pending.
DAREearnings

Earnings reactions, page 2

Daré Bioscience, Inc. (DARE) Q3 FY2026 earnings

November 17, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue for the three months ended September 30, 2026 was $47,628.
  • Selling, general and administrative expenses were $2,640,388 for the three months ended September 30, 2026.
  • Research and development expenses were $318,906 for the three months ended September 30, 2026.
  • Total contra-R&D expenses for the three months ended September 30, 2026 were approximately $4.7 million.
  • Cash and cash equivalents were $11,531,684 as of September 30, 2026.

Guidance

  • The Company does not expect the amount of product revenue from Flora Sync LF5 and DARE to PLAY Sildenafil Cream to be material during 2026.
  • Revenue from DARE to RECLAIM estradiol and progesterone intravaginal ring is targeted to begin in 2027.

Notes

The Company recognizes amounts received under grant and governmental funding awards as contra-R&D expenses.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →